a wholly owned subsidiary of La Jolla Pharmaceutical Company

Our Company

Committed to a Brighter Outlook

According to The Review on Antimicrobial Resistance (May 2016), by 2050, antimicrobial resistance is projected to kill more people than cancer and diabetes combined. At Tetraphase, the fight against antimicrobial resistance is at the core of who we are as a company. It unites us in a common goal and fueled our determination to develop new antibiotics that can overcome the challenges of drug-resistant bacteria and ensure the availability of effective treatments in the future. Our efforts have yielded our currently marketed antibacterial, XERAVA™ (eravacycline) for injection, as well as several promising investigational compounds that are currently available for out-licensing.

Please contact us to learn more.

Our Mission

Filled With Promise. Empowered by Passion.

Tetraphase is fighting one of the most significant threats to humanity — antibiotic resistance — through the promise of our technology and the passion of our people. We are committed to making novel antibiotics accessible to all patients in need.


Please enter a valid email address.


Please enter a valid email address.

Share information about Tetraphase


Thank you!
Your email has been sent.

Thank you for your request.

Someone will contact you shortly.